肾动脉瘤的自然病史
单中心回顾性分析2015至2019年经CT诊断的331例患者共338个肾动脉瘤,平均诊断直径12.9±5.9 mm,137例有影像随访者中43例(31.4%)增大,平均增长率0.23±4.7 mm/年,8例接受干预,无破裂;多因素分析中肥胖与增大显著相关(P = .04),初始直径>25 mm与后续干预显著相关(P = .006)。
要点
- 大多数肾动脉瘤在随访中保持大小稳定,仅少数达到指南干预指征。
- 肥胖与肾动脉瘤增大显著相关(P = .04)。
- 初始直径>25 mm与后续干预显著相关(P = .006),但与增大无显著相关。
核心结论
- 该大型机构队列发现大多数肾动脉瘤大小保持稳定,少数患者符合基于学会指南的修复指征。
- 鉴于肾动脉瘤进展缓慢,当前指南推荐对无症状且大于30 mm的动脉瘤进行干预似乎是合适的。
研究设计与样本
- 单机构回顾性分析,研究2015年至2019年间经计算机断层扫描成像诊断的所有肾动脉瘤患者,通过机构放射学数据库识别。
- 通过电子病历获取影像、人口学和临床数据,对所有有放射学随访的患者计算增长率。
- 队列包括331例患者共338个肾动脉瘤。
主要发现
- 大多数患者为女性(61.3%),11例(3.3%)处于育龄期;诊断时平均年龄71.5岁(范围24-99岁)。
- 合并症包括高血压(73.7%)、既往吸烟(34.4%)和结缔组织病(3.9%)。
- 影像学指征包括腹痛(33.5%)、无关随访(29.6%)和研究期前最初诊断的肾动脉瘤随访(10.7%)。
- 诊断时平均直径为12.9 ± 5.9 mm;尺寸分布包括小于<15 mm(69.9%)、15至25 mm(27.1%)和大于25 mm(3.0%)。
- 解剖位置包括远端肾动脉(26.7%)、肾门(42.4%)和肾动脉中段(13.1%);大多数为真性动脉瘤(98%),其中72.3%为梭形,27.7%为囊状;其他特征包括钙化(82.2%)、血栓(15.9%)和夹层(0.9%)。
关键数值与推荐
- 当前指南推荐对无症状且大于30 mm的动脉瘤进行干预。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The existing renal artery aneurysm (RAA) literature is largely composed of reports of patients who underwent intervention. The objective of this study was to review the natural history of RAA. METHODS: This single-institution retrospective analysis studied all patients with RAA diagnosed by computed tomography imaging between 2015 and 2019, identified by our institutional radiology database. Imaging, demographic, and clinical data were obtained via the electronic medical record. He growth rate was calculated for all patients with radiological follow-up. RESULTS: The cohort consists of 331 patients with 338 RAAs. Most patients were female (61.3%), with 11 (3.3%) of childbearing age. The mean age at diagnosis was 71.5 years (range, 24-99 years). Medical comorbidities included hypertension (73.7%), prior smoking (34.4%), and connective tissue disease (3.9%). Imaging indications included abdominal pain (33.5%), unrelated follow-up (29.6%), and follow-up of an RAA initially diagnosed before the study period (10.7%). Right RAA (61.9%) was more common than left (35.1%); 3% of patients had bilateral RAA. The mean diameter at diagnosis was 12.9 ± 5.9 mm. Size distribution included lesions measuring less than <15 mm (69.9%), 15 to 25 mm (27.1%), and more than 25 mm (3.0%). Anatomic locations included the distal RA (26.7%), renal hilum (42.4%), and mid-RA (13.1%). The majority were true aneurysms (98%); of these, 72.3% were fusiform and 27.7% were saccular. Additional characteristics included calcification (82.2%), thrombus (15.9%), and dissection (0.9%). Associated findings included aortic atherosclerosis (65.6%), additional visceral aneurysms (7.3%), and abdominal aortic aneurysm (5.7%). The mean clinical follow-up among 281 patients was 41.0 ± 24.0 months. The mean radiological follow-up among 137 patients was 26.0 ± 21.4 months. Of these, 43 patients (31.4%) experienced growth, with mean growth rate of 0.23 ± 4.7 mm/year; the remainder remained stable in size. Eight patients eventually underwent intervention (5 endovascular), with the most common indications including size criteria (4/8) and symptom development (3/8). No patient developed rupture. On multivariate analysis, obesity (P = .04) was significantly associated with growth. An initial diameter of more than 25 mm was significantly associated with subsequent intervention (P = .006), but was not significantly associated with growth. Four of five RAAs with an initial diameter 30 mm or greater did not undergo intervention. The mean clinical follow-up for these patients was 24 months; none developed rupture and two remained stable in size. CONCLUSIONS: This large institutional cohort found that the majority of RAAs remained stable in size, with few patients meeting indications for repair based on societal guidelines. Current guidelines recommending intervention for asymptomatic aneurysms more than 30 mm seem to be appropriate given their slow progression.
引用
- Zhang J, Harish K, Speranza G, et al. Natural history of renal artery aneurysms. J Vasc Surg. 2022. PMID: 36375725. doi:10.1016/j.jvs.2022.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。